Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb; 14(2):134-40.
View in:
PubMed
subject areas
Adult
Adult
Aged
Aged
Benzimidazoles
Benzimidazoles
Cystadenocarcinoma, Serous
Cystadenocarcinoma, Serous
Female
Female
Humans
Humans
MAP Kinase Signaling System
MAP Kinase Signaling System
Middle Aged
Middle Aged
Mitogen-Activated Protein Kinase Kinases
Mitogen-Activated Protein Kinase Kinases
Mutation
Mutation
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Ovarian Neoplasms
Ovarian Neoplasms
Peritoneal Neoplasms
Peritoneal Neoplasms
Proto-Oncogene Proteins
Proto-Oncogene Proteins
Proto-Oncogene Proteins B-raf
Proto-Oncogene Proteins B-raf
Proto-Oncogene Proteins p21(ras)
Proto-Oncogene Proteins p21(ras)
ras Proteins
ras Proteins
authors with profiles
Robert S Mannel